Skip to Main Content

Author Details

Thomas M Pisansky
Mayo Clinic
1992
179
53
PMIDPaper TitleJournal TitlePublished Year
36710205Effects of Androgen Deprivation Therapy on Prostate Cancer Outcomes According to Competing Event Risk: Secondary Analysis of a Phase 3 Randomised Trial.Eur Urol2024
36269935Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials.J Clin Oncol2023
36922081Androgen Suppression Combined With Elective Nodal and Dose Escalated Radiation Therapy: Brachytherapy as Dose Escalation for Localized Prostate Cancer.Int J Radiat Oncol Biol Phys2023
36427645Late Toxicity of Moderately Hypofractionated Intensity-Modulated Proton Therapy Treating the Prostate and Pelvic Lymph Nodes for High-Risk Prostate Cancer.Int J Radiat Oncol Biol Phys2023
36736921Neighborhood Deprivation and Rurality Associated With Patient-Reported Outcomes and Survival in Men With Prostate Cancer in NRG Oncology RTOG 0415.Int J Radiat Oncol Biol Phys2023
36179990External Beam Radiation Therapy With or Without Brachytherapy Boost in Men With Very-High-Risk Prostate Cancer: A Large Multicenter International Consortium Analysis.Int J Radiat Oncol Biol Phys2023
34740768Salvage Low-Dose-Rate Prostate Brachytherapy: Clinical Outcomes of a Phase 2 Trial for Local Recurrence after External Beam Radiation Therapy (NRG Oncology/RTOG 0526).Int J Radiat Oncol Biol Phys2022
35737923Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601.J Clin Oncol2022
35776901Methodological Comparison of Mapping the Expanded Prostate Cancer Index Composite to EuroQoL-5D-3L Using Cross-Sectional and Longitudinal Data: Secondary Analysis of NRG/RTOG 0415.JCO Clin Cancer Inform2022
35934601Local Failure Events in Prostate Cancer Treated with Radiotherapy: A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN).Eur Urol2022
35051385Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis.Lancet Oncol2022
35050303Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts.JAMA Oncol2022
32861817NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer.Int J Radiat Oncol Biol Phys2021
33852571Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415.PLoS One2021
33570548Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial.JAMA Oncol2021
33636378Predictors of Locoregional Recurrence and Delineation of Adjuvant Radiation Therapy Fields for Patients With Upper Tract Urothelial Carcinoma Receiving Nephroureterectomy.Pract Radiat Oncol2021
33885704Evaluation of Safety of Stereotactic Body Radiotherapy for the Treatment of Patients With Multiple Metastases: Findings From the NRG-BR001 Phase 1 Trial.JAMA Oncol2021
34964855Comparison of Response to Definitive Radiotherapy for Localized Prostate Cancer in Black and White Men: A Meta-analysis.JAMA Netw Open2021
34902034Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer.JAMA Netw Open2021
34722810Proton Therapy of Prostate and Pelvic Lymph Nodes for High Risk Prostate Cancer: Acute Toxicity.Int J Part Ther2021
34593526Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in <sup>11</sup>C-Choline-PET/CT-Identified Oligometastatic Castration-Resistant Prostate Cancer.Clin Cancer Res2021
33985797Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer.Eur Urol2021
34196715Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features.JAMA Netw Open2021
34023327The prognostic value, sensitivity, and specificity of multiparametric magnetic resonance imaging before salvage radiotherapy for prostate cancer.Radiother Oncol2021
33275486Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis.J Clin Oncol2021
32109600Outcomes and Profiles of Older Patients Receiving Definitive Radiation Therapy for Muscle-Invasive Bladder Cancer at a Tertiary Medical Center.Pract Radiat Oncol2020
33090219Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate.JAMA Oncol2020
32931662Comparing bowel and urinary domains of patient-reported quality of life at the end of and 3 months post radiotherapy between intensity-modulated radiotherapy and proton beam therapy for clinically localized prostate cancer.Cancer Med2020
32931029Impact of adjuvant trastuzumab on locoregional failure rates in a randomized clinical trial: North Central Cancer Treatment Group N9831 (alliance) study.Cancer2020
32215583Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer.JAMA Oncol2020
30312717A Prospective Phase 2 Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer After External Beam Radiation Therapy (NRG Oncology/RTOG-0526).Int J Radiat Oncol Biol Phys2019
31540746Gleason pattern 5 is associated with an increased risk for metastasis following androgen deprivation therapy and radiation: An analysis of RTOG 9202 and 9902.Radiother Oncol2019
31015166Tolerance doses for late adverse events after hypofractionated radiotherapy for prostate cancer on trial NRG Oncology/RTOG 0415.Radiother Oncol2019
31042111Adjuvant and Salvage Radiotherapy after Prostatectomy: ASTRO/AUA Guideline Amendment 2018-2019.J Urol2019
31011676Single-fraction Stereotactic Body Radiation Therapy versus Conventionally Fractionated Radiation Therapy for the Treatment of Prostate Cancer Bone Metastases.Adv Radiat Oncol2019
31120534Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality.JAMA Oncol2019
31060795The current state of randomized clinical trial evidence for prostate brachytherapy.Urol Oncol2019
31051281Adjuvant and Salvage Radiation Therapy After Prostatectomy: ASTRO/AUA Guideline Amendment, Executive Summary 2018.Pract Radiat Oncol2019
30959123Prostate-Specific Antigen After Neoadjuvant Androgen Suppression in Prostate Cancer Patients Receiving Short-Term Androgen Suppression and External Beam Radiation Therapy: Pooled Analysis of Four NRG Oncology Radiation Therapy Oncology Group Randomized Clinical Trials.Int J Radiat Oncol Biol Phys2019
30526194Time Interval to Biochemical Failure as a Surrogate End Point in Locally Advanced Prostate Cancer: Analysis of Randomized Trial NRG/RTOG 9202.J Clin Oncol2019
30293836Permanent prostate brachytherapy monotherapy with I-125 for low- and intermediate-risk prostate cancer: Outcomes in 974 patients.Brachytherapy2019
29128208Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer.Eur Urol2018
32775476Increased utilization of external beam radiotherapy relative to cystectomy for localized, muscle-invasive bladder cancer: a SEER analysis.Bladder (San Franc)2018
30183466Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline.J Clin Oncol2018
30316827Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial.Lancet Oncol2018
29372236Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features.JAMA Oncol2018
28068253In Reply to Ghadjar et al.Int J Radiat Oncol Biol Phys2017
28463149Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202.Int J Radiat Oncol Biol Phys2017
28486040GATA2 expression and biochemical recurrence following salvage radiation therapy for relapsing prostate cancer.Br J Radiol2017
28135134Reply to T. Seisen et al and P. Ghadjar et al.J Clin Oncol2017
  • 1 - 50 of 179

Recommended Authors

R Jeffrey Karnes
Mayo Clinic
Career Start Year 2013
Number of shared co-authors 28
Rachel M Glicksman
University of Toronto, Princess Margaret Cancer Centre, University Health Network
Career Start Year 2013
Number of shared co-authors 25
Matthew P Deek
Rutgers Robert Wood Johnson Medical School, Rutgers University
Career Start Year 2011
Number of shared co-authors 31
Xin Pei
Memorial Sloan Kettering Cancer Center
Career Start Year 2010
Number of shared co-authors 6
Alan Dal Pra
University of Miami Miller School of Medicine
Career Start Year 2010
Number of shared co-authors 22
Suneil Jain
Cancer Centre Belfast City Hospital, Queen's University Belfast
Career Start Year 2008
Number of shared co-authors 14
John Thoms
Memorial University
Career Start Year 2008
Number of shared co-authors 5
Jure Murgic
University Hospital Center Sestre Milosrdnice
Career Start Year 2008
Number of shared co-authors 8
Himanshu Nagar
New York-Presbyterian Hospital, Weill Cornell Medical Center
Career Start Year 2005
Number of shared co-authors 18
Nicholas van As
The Institute of Cancer Research, Royal Marsden NHS Foundation Trust
Career Start Year 2005
Number of shared co-authors 6
Ananya Choudhury
University of Manchester and The Christie NHS Foundation Trust
Career Start Year 2004
Number of shared co-authors 19
Neil B Desai
University of Texas Southwestern Medical Center
Career Start Year 2004
Number of shared co-authors 33
Piet Ost
Ghent University, GZA Ziekenhuizen
Career Start Year 2002
Number of shared co-authors 43
Zhigang Zhang
Memorial Sloan Kettering Cancer Center
Career Start Year 2001
Number of shared co-authors 8
Andrew K Lee
Texas Center for Proton Therapy
Career Start Year 2001
Number of shared co-authors 4
Danny Vesprini
University of Toronto, Canada Odette Cancer Centre
Career Start Year 1998
Number of shared co-authors 8
Gert De Meerleer
University Hospitals Leuven
Career Start Year 1997
Number of shared co-authors 27
Constantine A Mantz
University of Chicago
Career Start Year 1997
Number of shared co-authors 33
Simeng Suy
MedStar Georgetown University Hospital
Career Start Year 1996
Number of shared co-authors 33
Vincent Khoo
The Royal Marsden NHS Foundation Trust and Institute of Cancer Research
Career Start Year 1996
Number of shared co-authors 16
Alan W Katz
University of Rochester
Career Start Year 1996
Number of shared co-authors 25
Laurence Collette
Belgium International Drug Development Institute
Career Start Year 1995
Number of shared co-authors 26
Markus Graefen
University Hospital Frankfurt, Goethe University Frankfurt am Main
Career Start Year 1993
Number of shared co-authors 22
Christopher R King
University of California los angeles
Career Start Year 1988
Number of shared co-authors 59
Donald B Fuller
Division of Genesis Healthcare Partners Inc., CyberKnife Centers of San Diego Inc.
Career Start Year 1986
Number of shared co-authors 21
Peter Hoskin
Mount Vernon Cancer Centre
Career Start Year 1985
Number of shared co-authors 35
Joseph L Chin
University of Western Ontario
Career Start Year 1982
Number of shared co-authors 14
Andre Konski
Chester County Hospital
Career Start Year 1982
Number of shared co-authors 19
Philip W Kantoff
Memorial Sloan Kettering Cancer Center
Career Start Year 1981
Number of shared co-authors 41
Mario A Eisenberger
Johns Hopkins University
Career Start Year 1977
Number of shared co-authors 30

Collaborators

Howard M Sandler
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Co-authored papers 46
Brian J Davis
Mayo Clinic
Co-authored papers 42
Jeff M Michalski
Washington University School of Medicine
Co-authored papers 37
Eric M Horwitz
Fox Chase Cancer Center
Co-authored papers 29
Felix Y Feng
UCSF Medical Center-Mount Zion
Co-authored papers 21
Bradley J Stish
Mayo Clinic
Co-authored papers 21
William Robert Lee
Duke University School of Medicine
Co-authored papers 19
Daniel E Spratt
University Hospitals Seidman Cancer Center, Case Western Reserve University
Co-authored papers 19
Richard Choo
Mayo Clinic
Co-authored papers 18
Patrick A Kupelian
university of california los angeles Medical Center
Co-authored papers 17
Seth A Rosenthal
Sutter Cancer Centers Radiation Oncology Services
Co-authored papers 15
Mack Roach
University of California San Francisco
Co-authored papers 14
Amar U Kishan
University of California los angeles
Co-authored papers 13
Alan Pollack
University of Miami Miller School of Medicine
Co-authored papers 13
Robert T Dess
University of Michigan ann arbor
Co-authored papers 12
Rahul D Tendulkar
Taussig Cancer Institute, Cleveland Clinic
Co-authored papers 11
Deborah W Bruner
Emory University, USA Winship Cancer Institute, USA School of Medicine
Co-authored papers 11
Robert Jeffrey Karnes
Mayo Clinic
Co-authored papers 10
Matthew B Rettig
David Geffen School of Medicine, University of California los angeles
Co-authored papers 9
Theodore L DeWeese
Johns Hopkins University School of Medicine
Co-authored papers 9
Nicholas G Nickols
University of California, Veteran Affairs Greater Los Angeles Healthcare System
Co-authored papers 9
Michael L Steinberg
University of California los angeles
Co-authored papers 9
Tahmineh Romero
David Geffen School of Medicine at university of california los angeles
Co-authored papers 9
Robert E Reiter
David Geffen School of Medicine at university of california los angeles
Co-authored papers 8
Phuoc T Tran
University of Maryland School of Medicine
Co-authored papers 8
James N Ingle
Mayo Clinic
Co-authored papers 8
Vera J Suman
Mayo Clinic
Co-authored papers 8
Paul L Nguyen
Brigham and Women's Hospital and Dana Farber Cancer Institute, Harvard Medical School
Co-authored papers 8
Stephanie L Pugh
Co-authored papers 8
Bridget F Koontz
Duke University School of Medicine
Co-authored papers 7
Release 1.2